Navigation Links
Ash Stevens Plans $6 Million Facility Expansion to Bolster CMC Capabilities
Date:9/30/2009

Ash Stevens, Incorporated (ASI), a full service contract drug development and cGMP manufacturer, announced that the company is in the initial phases of a multi-year $6 million expansion project to upgrade the capacity and capabilities of its Active Pharmaceutical Ingredient (API) manufacturing facility located in Riverview, Michigan. Expansions will include a new reactor bay and warehouse.

Detroit, MI (PRWEB) September 30, 2009 -- Ash Stevens, Incorporated (ASI), a full service contract drug development and cGMP manufacturer, announced that the company is in the initial phases of a multi-year expansion project to upgrade the capacity and capabilities of its Active Pharmaceutical Ingredient (API) manufacturing facility located in Riverview, Michigan. Expenditures for the initial phases of the project will total more than $6 million and will include a new reactor bay and warehouse. The investment will add significant capacity and additional capabilities to the existing ASI facility as part of ASI's on-going commitment to provide the company's clients with the highest quality of service, safety, and on-time delivery of APIs.

To be operational in January 2010, the plan's initial phase calls for an isolated new reactor bay, which will house two 100-gallon glass-lined reactors and a 50-gallon hydrogenation vessel. The new reactor bay will provide redundant capacity to a similarly designed existing bay that holds three 100-gallon reactors, while providing additional plant capacity and plant-scale hydrogenation capabilities.

In June of 2010, ASI will occupy a new 10,000 square foot warehouse facility. Completion of the state-of-the-art reactor bay and warehouse facility will set the stage for execution of the next phases of the expansion plan.

"The new bay and warehouse represent a self-financed $6 million investment for ASI. The continuous upgrading and modernization of our operations is an essential component of our business model to provide our clients the highest quality of service while ensuring delivery of their API on time and on schedule from a safe and environmentally friendly facility. As we increase our efficiencies with larger equipment, we also enhance our cost-effectiveness, further benefiting our customers," said Dr. Stephen Munk, President and CEO of Ash Stevens.

Subsequent phases of the expansion plan call for a new large-scale reactor bay, process development labs, and additional facilities to handle highly potent APIs.

For more information, visit Ash Stevens at CPhI Worldwide in Madrid, Spain, booth #NB403 located in the New Business Pavillion on October 16-19, 2009 or online at www.ashstevens.com. James M. Hamby, R.Ph., Ph.D., Vice President of Business Development for Ash Stevens, Inc. will be speaking on the topic of Managing CMC Development for FDA Fast-Tracked Drugs on Tuesday, October 13 at 2:00 p.m.

About Ash Stevens, Inc.
Headquartered in Detroit, Ash Stevens, Inc. (ASI) was founded in 1962 to service the chemical research needs of the Federal Government. ASI has extensive experience in the development and scale-up of commercial cancer APIs and shares a longstanding and successful relationship with the National Cancer Institute. ASI has a total of 11 FDA approved drug substances in its portfolio. The company has more than 60 employees and holds a variety of patents covering topics including medicinal agents and manufacturing processes. For more information, visit www.ashstevens.com.

###

Read the full story at http://www.prweb.com/releases/2009/09/prweb2966284.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Ash Stevens Inc. Named One of Michigan 50 Companies to Watch
2. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
3. Dr. Dinesh Verma to be honored with Presidents Leadership Award at Edwin A. Stevens Society Gala
4. The USC Stevens Institute for Innovation Opens Shop on USC Health Sciences Campus
5. Stevens researchers provide new information about mass spectrometry
6. The USC Stevens Institute for Innovation Opens Shop on US Health Sciences Campus
7. Stevens to host Nanoscience/Nanotechnology & Corrosion symposium, Nov. 13
8. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
9. Cardium Provides Update on Phase 2b Excellarate Clinical Study and Plans for Additional Tissue Repair Applications
10. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
11. Dow AgroSciences, Monsanto Complete U.S. and Canadian Regulatory Authorizations for SmartStax Corn; Plans Set to Launch Seed Platform on 3 Million- to 4 Million-Plus Acres
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... After spending the past two years building a state-of-the-art technology which ... offers this platform to healthcare stakeholders (hospitals, foundations, biopharma companies etc.) ... collection vis a vis their members, under their own brand. Three ... offer. ... ...
(Date:8/15/2017)... ... August 15, 2017 , ... Any expert in stem cell research ... disciplines for more than half a century. Despite their essential roles in human ... widely known that molecular tags developed for this purpose also tag other, more abundant, ...
(Date:8/15/2017)... , ... August 15, 2017 , ... ... shopping cart. Now mobile responsive, the new website makes it easy to navigate ... in between. Users can now find detailed product information, educational industry content and ...
(Date:8/11/2017)... 2017  Market researcher Kalorama Information was ... regarding the telemedicine market.  The telemedicine market ...  The article, "Heart and Asthma Monitors? ... information from Kalorama Information,s Remote Patient Monitoring ...  (Sleep, Diabetes, Vital Signs /EKG and ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/5/2017)... -- KEY FINDINGS The global market for ... of 25.76% during the forecast period of 2017-2025. The ... the growth of the stem cell market. ... INSIGHTS The global stem cell market is segmented on ... stem cell market of the product is segmented into ...
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
Breaking Biology News(10 mins):